SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Schrag D, Garewal HS, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004; 22: 3631-3638.
  • 2
    NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer, version 1.2011j. Available at: www.NCCN.org Accessed on December 12, 2010.
  • 3
    Kravtsov V, Fabian I. Automated monitoring of apoptosis in suspension cell cultures. Lab Invest. 1996; 74: 557-570.
  • 4
    Kravtsov V, Greer J, Whitlock J, Koury M. Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias. Blood. 1998; 92: 968-980.
  • 5
    Kravtsov V, Greer J, Shyr Y, et al. Prediction of survival in acute nonlymphocytic leukemia. Blood. 2001; 98: 214b.
  • 6
    Whitworth PW, Presant CA, Rutledge J, et al. Chemosensitivity of patient breast cancer cells in vitro: correlation with prior chemotherapy and implications for personalized treatment planning [abstract]. J Clin Oncol. 2009; 27( suppl). Abstract e11563A.
  • 7
    Ballard KS, Homesley HD, Hodson C, et al. Endometrial carcinoma in-vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic (MiCK) apoptosis assay: implications for endometrial cancer treatment. J Gynecol Oncol. 2010; 21: 45-59.
  • 8
    Salom EM, Homesley HD, Presant CA, et al. Can we increase response rate and overall survival by individualizing chemotherapy in ovarian cancer—the role of new chemotherapy induced apoptosis assay [abstract]. J Clin Oncol. 2010; 28( suppl 15s). Abstract 5112.
  • 9
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 10
    Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc. 1972; 135: 185-207.
  • 11
    Fisher RA. Statistical Methods for Research Workers. Edinburgh, UK: Oliver and Boyd; 1954.
  • 12
    Latimer G, Presant CA, Hallquist A, et al. The value of personalized treatment planning: cost savings by the microculture kinetic chemosensitivity assay, evidence from a large American self-insured company [abstract]. J Clin Oncol. 2009; 27( suppl). Abstract e17.
  • 13
    Von Hoff DD, Stephenson JJJr, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010; 28: 4877-4883.
  • 14
    Doroshow JH. Selecting systemic cancer therapy 1 patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol. 2010; 28: 4869-4871.
  • 15
    MacConaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol. 2010; 28: 5219-5228.
  • 16
    Hirsch FR, Wynes MW, Gandara DR, et al. The tissue is the issue: personalized medicine for nonsmall cell lung cancer. Clin Cancer Res. 2010; 16: 4909-4911.